TY - JOUR
T1 - Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder
AU - Hollander, Eric
AU - Soorya, Latha
AU - Wasserman, Stacey
AU - Esposito, Katherine
AU - Chaplin, William
AU - Anagnostou, Evdokia
PY - 2006/4
Y1 - 2006/4
N2 - Autism is a neurodevelopmental disorder characterized by impairment in three core symptom domains: socialization, communication, and repetitive/stereotyped behaviours. Other associated symptom domains are also affected including impulsivity/aggression, self-injury, anxiety, and mood lability. Divalproex has been shown to have efficacy in treating epilepsy, bipolar disorder, mood lability, and impulsive aggression. The present study evaluated the use of divalproex in the treatment of repetitive, compulsive-like symptoms of autism spectrum disorder (ASD). Thirteen individuals with ASD participated in an 8-wk, double-blind, placebo-controlled trial of divalproex sodium vs. placebo. There was a significant group difference on improvement in repetitive behaviours as measured by the Children's Yale-Brown Obsessive Compulsive Scale (C-YBOCS) (p = 0.037) and a large effect size (d = 1.616). This study provides preliminary support for the use of divalproex in treating repetitive behaviours in ASD. Further research is needed to evaluate the specificity and mechanism of action of these findings.
AB - Autism is a neurodevelopmental disorder characterized by impairment in three core symptom domains: socialization, communication, and repetitive/stereotyped behaviours. Other associated symptom domains are also affected including impulsivity/aggression, self-injury, anxiety, and mood lability. Divalproex has been shown to have efficacy in treating epilepsy, bipolar disorder, mood lability, and impulsive aggression. The present study evaluated the use of divalproex in the treatment of repetitive, compulsive-like symptoms of autism spectrum disorder (ASD). Thirteen individuals with ASD participated in an 8-wk, double-blind, placebo-controlled trial of divalproex sodium vs. placebo. There was a significant group difference on improvement in repetitive behaviours as measured by the Children's Yale-Brown Obsessive Compulsive Scale (C-YBOCS) (p = 0.037) and a large effect size (d = 1.616). This study provides preliminary support for the use of divalproex in treating repetitive behaviours in ASD. Further research is needed to evaluate the specificity and mechanism of action of these findings.
KW - Autism
KW - Divalproex
KW - Repetitive behaviours
KW - Valproate
UR - http://www.scopus.com/inward/record.url?scp=32844464646&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=32844464646&partnerID=8YFLogxK
U2 - 10.1017/S1461145705005791
DO - 10.1017/S1461145705005791
M3 - Article
C2 - 16316486
AN - SCOPUS:32844464646
SN - 1461-1457
VL - 9
SP - 209
EP - 213
JO - International Journal of Neuropsychopharmacology
JF - International Journal of Neuropsychopharmacology
IS - 2
ER -